Carlos de Castro

Overview:

Clinical research projects have focused on new and innovative treatments for myelodysplastic syndromes, paroxysmal nocturnal hemoglobinuria, adult leukemias, and lymphomas

Positions:

Professor of Medicine

Medicine, Hematologic Malignancies and Cellular Therapy
School of Medicine

Member of the Duke Cancer Institute

Duke Cancer Institute
School of Medicine

Education:

M.D. 1985

University of Texas at Dallas

Resident, Medicine

University of Texas at Dallas

Fellow in Hematology-Oncology, Medicine

Duke University

Grants:

EQAPOL - Years 2017 to 2024 - BASE

Administered By
Duke Human Vaccine Institute
Awarded By
National Institutes of Health
Role
Director
Start Date
End Date

Eqapol Opt 1 -2018-2019

Administered By
Duke Human Vaccine Institute
Awarded By
National Institutes of Health
Role
Medical Director
Start Date
End Date

EQAPOL Option 5

Administered By
Duke Human Vaccine Institute
Awarded By
National Institutes of Health
Role
Investigator
Start Date
End Date

A Phase III, Randomized, Multi-Center, Open-Label, Active-Comparator Controlled Study To Evaluate the Efficacy and Safety of APL-2 in Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH)

Administered By
Duke Cancer Institute
Awarded By
Apellis Pharmaceuticals, Inc
Role
Principal Investigator
Start Date
End Date

A Phase 1b/2 Study of Entospletinib (GS-9973) Monotherapy and in Combination with Chemotherapy in Patients with Acute Myeloid Leukemia (AML)

Administered By
Duke Cancer Institute
Awarded By
Gilead Sciences, Inc.
Role
Principal Investigator
Start Date
End Date

Publications:

Myelodysplastic Syndromes, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology.

The myelodysplastic syndromes (MDS) comprise a heterogenous group of myeloid disorders with a highly variable disease course. Diagnostic criteria to better stratify patients with MDS continue to evolve, based on morphology, cytogenetics, and the presence of cytopenias. More accurate classification of patients will allow for better treatment guidance. Treatment encompasses supportive care, treatment of anemia, low-intensity therapy, and high-intensity therapy. This portion of the guidelines focuses on diagnostic classification, molecular abnormalities, therapeutic options, and recommended treatment approaches.
Authors
Greenberg, PL; Stone, RM; Al-Kali, A; Barta, SK; Bejar, R; Bennett, JM; Carraway, H; De Castro, CM; Deeg, HJ; DeZern, AE; Fathi, AT; Frankfurt, O; Gaensler, K; Garcia-Manero, G; Griffiths, EA; Head, D; Horsfall, R; Johnson, RA; Juckett, M; Klimek, VM; Komrokji, R; Kujawski, LA; Maness, LJ; O'Donnell, MR; Pollyea, DA; Shami, PJ; Stein, BL; Walker, AR; Westervelt, P; Zeidan, A; Shead, DA; Smith, C
MLA Citation
Greenberg, Peter L., et al. “Myelodysplastic Syndromes, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology.J Natl Compr Canc Netw, vol. 15, no. 1, Jan. 2017, pp. 60–87. Pubmed, doi:10.6004/jnccn.2017.0007.
URI
https://scholars.duke.edu/individual/pub1226019
PMID
28040720
Source
pubmed
Published In
J Natl Compr Canc Netw
Volume
15
Published Date
Start Page
60
End Page
87
DOI
10.6004/jnccn.2017.0007

MicroRNA expression in red blood cells from patients with PNH

Authors
Chi, J-TA; Sangokoya, C; De Castro, CM
MLA Citation
Chi, Jen-Tsan Ashley, et al. “MicroRNA expression in red blood cells from patients with PNH.” Blood, vol. 110, no. 11, AMER SOC HEMATOLOGY, 2007, pp. 1073A-1073A.
URI
https://scholars.duke.edu/individual/pub927183
Source
wos
Published In
Blood
Volume
110
Published Date
Start Page
1073A
End Page
1073A

Morphologic leukemia-free state in acute myeloid leukemia is sufficient for successful allogeneic hematopoietic stem cell transplant.

Authors
Pabon, CM; Li, Z; Hennig, T; de Castro, C; Neff, JL; Horwitz, ME; LeBlanc, TW; Long, GD; Lopez, RD; Sung, AD; Chao, N; Gasparetto, C; Sarantopoulos, S; Adams, DB; Erba, H; Rizzieri, DA
MLA Citation
Pabon, Cindy M., et al. “Morphologic leukemia-free state in acute myeloid leukemia is sufficient for successful allogeneic hematopoietic stem cell transplant.Blood Cancer J, vol. 11, no. 5, May 2021, p. 92. Pubmed, doi:10.1038/s41408-021-00481-9.
URI
https://scholars.duke.edu/individual/pub1482850
PMID
33994546
Source
pubmed
Published In
Blood Cancer Journal
Volume
11
Published Date
Start Page
92
DOI
10.1038/s41408-021-00481-9

Results of the Pegasus Phase 3 Randomized Trial Demonstrating Superiority of the C3 Inhibitor, Pegcetacoplan, Compared to Eculizumab in Patients with Paroxysmal Nocturnal Hemoglobinuria

Authors
Griffin, M; Hillmen, P; Szer, J; Weitz, IC; Roeth, A; Hoechsmann, B; Panse, J; Usuki, K; Kiladjian, J-J; De Castro, CM; Nishimori, H; Tan, L; Hamdani, M; Deschatelets, P; Francois, C; Grossi, F; Risitano, A; De Latour, RP
URI
https://scholars.duke.edu/individual/pub1483488
Source
wos-lite
Published In
British Journal of Haematology
Volume
193
Published Date
Start Page
63
End Page
65

P132 Cost of transfusion dependency among managed care patients with myelodysplastic syndromes

Authors
Frytak, JR; Henk, HJ; de Castro, CM; Halpern, R; Nelson, M
MLA Citation
Frytak, J. R., et al. “P132 Cost of transfusion dependency among managed care patients with myelodysplastic syndromes.” Leukemia Research, vol. 31, Elsevier BV, May 2007, pp. S111–12. Crossref, doi:10.1016/s0145-2126(07)70202-3.
URI
https://scholars.duke.edu/individual/pub927196
Source
crossref
Published In
Leukemia Research
Volume
31
Published Date
Start Page
S111
End Page
S112
DOI
10.1016/s0145-2126(07)70202-3